Abstract
Airways disease is a frequent problem poorly recognised in older people. Many have reversible airway limitation and do not receive appropriate therapy. As in younger patients, pulmonary function tests are essential as a baseline and in relation to formal trials of treatment in both the diagnosis and management. Preferably, the assessment of all patients with airflow limitation should include a corticosteroid trial to correctly identify all patients who need long term prophylactic therapy. Many older patients have difficulty using the metered dose inhalers and the addition of volume spacer devices, though cumbersome, has many further advantages. In some patients, airflow limitation may be complicated by the presence of cardiac failure, arrhythmias and arterial hypoxia, and these problems also need to be reviewed.
Sign-in/Register to access full text options 
Talk to us
Join us for a 30 min session where you can share your feedback and ask us any queries you have
Schedule a callDisclaimer: All third-party content on this website/platform is and will remain the property of their respective owners and is provided on "as is" basis without any warranties, express or implied. Use of third-party content does not indicate any affiliation, sponsorship with or endorsement by them. Any references to third-party content is to identify the corresponding services and shall be considered fair use under The CopyrightLaw.
